期刊文献+

基质金属蛋白酶及其抑制剂与高血压病的研究进展 被引量:2

Research Progress of Matrix Metalloproteinases and Their Inhibitors in Hypertension
下载PDF
导出
摘要 基质金属蛋白酶是一族Zn2+依赖的蛋白水解酶,主要负责组织重塑与细胞外基质的降解,能够降解细胞外基质,在胚胎的发育、组织重构、炎症调控、肿瘤疾病等多种生理过程中起重要作用。现就其在高血压病的发生、发展及靶器官功能损害中的作用机制、临床意义及其治疗新进展阐述如下。 Matrix metalloproteinases are a family of Zn2 + dependent protein hydrolysis enzyme, are mainly responsible for the degra- dation of extracellular matrix and tissue remodeling, can degrade extracellular matrix, and play an important role in various physiological processes such as embryonic development, tissue remodeling, inflammation control, tumor disease, and so on. Now the mechanism of action in the occurrence and development of hypertension and target organ damage, clinical significance and treatment progress is elaborated in this paper.
作者 刘永 张艳敏
出处 《心血管病学进展》 CAS 2013年第6期818-822,共5页 Advances in Cardiovascular Diseases
关键词 基质金属蛋白酶 基质蛋白酶抑制剂 高血压 matrix metaltoproteinases matrix metalloproteinase inhibitors hypertension
  • 相关文献

参考文献34

  • 1Dhingra R,Pencina MJ,Schrader P,et al.Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community[J].Circulation,2009,119:1101-1107.
  • 2Flamant M,Plaeier S,Dubroca C,et al.Role of matrix metalloproteinases in early hypertensive vascular remodeling[J].Hypertens Res,2007,30(10):959-963.
  • 3Nagareddy PR,Chow FL,Hao L,et al.Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3k and mitochondrial ATP synthesis[J].Cardiovasc Res,2009,84(3):368-377.
  • 4Rodrigues SF,Tran ED,Fortes ZB,et al.Matrix metalloproteinases cleave the β2-adrenergic receptor in spontaneously hypertensive rats[J].Am J Physiol Heart Circ Physiol,2010,299:H25-H35.
  • 5Marchesi C,Dentali F,Nicolini E,et al.Plasma levels of matrix metalloproteinases and their inhibitors in hypertension:a systematic review and meta-analysis[J].J Hypertens,2012,30(1):3-16.
  • 6Nagareddy PR,Rajput PS,Vasudevan H,et al.Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats[J].Br J Pharmacol,2012,165(3):705-715.
  • 7Tran ED,DeLano AF,Schmid-Sch(o)nbein GW.Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat:VEGFR-2 cleavage,endothelial apoptosis,and capillary rarefaction[J].J Vasc Res,2010,47:423-431.
  • 8Tran ED,Chen A,DeLano FA,et al.Matrix metalloproteinase activity causes VEGFR-2 cleavage and microvascular rarefaction in rat mesentery[J].Microcirculation,2011,18(3):228-237.
  • 9Tan J,Hua Q,Xing X,et al.Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension[J].Hypertens Res,2007,30:959-963.
  • 10苏伟,高枫,龚少愚,张亦哲,陆曙.原发性高血压患者血清基质金属蛋白酶9与升主动脉弹性的关系[J].中华高血压杂志,2010,18(4):385-389. 被引量:12

二级参考文献19

  • 1郑孝志,季平,茅红卫.高血压病患者升主动脉弹性的应变率评价[J].临床超声医学杂志,2007,9(2):88-90. 被引量:9
  • 2Lehoux S, Lemarie CA, Esposito B, et al. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling[J]. Circulation,2004,109(8) :1041-1047.
  • 3Medley TL, Cole TJ, Dart AM, et al. Matrix metalloproteinase- 9 genotype influences large artery stiffness through effects on aortic gene and protein expression[J]. Arterioscler Thromb Vasc Biol,2004,24(8):1479-1484.
  • 4Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury[J]. Circ Res, 2002,91 (9): 845-851.
  • 5Dwivedi A, Slater SC, George SJ. MMP-9 and -12 cause N-cadherin shedding and thereby heta-catenin signalling and vascular smooth muscle cell proliferation[J]. Cardiovasc Res,2009,81( 1 ) : 178-186.
  • 6Yasmin, MeEniery CM, Wallace S, et al. Matrix metalloproteinase-9( MMP-9), MMP-2 and serum elastase activity are associated with systolic hypertension and arterial stiffness[J]. Arterioseler Thromb Vase Biol, 2005,25 (2) : 372-378.
  • 7Hansson L.The Hypertension Optimal Treatment study (the HOT Study).Blood Press,1993,2:62-68.
  • 8Hansson L,Zanchetti A,Carruthers SG,et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial.Lancet,1998,351:1755-1762.
  • 9Mancia G,De Backer G,Dominiczak A,et al.2007 Guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).J Hypertens,2007,25:1105-1187.
  • 10Romero JR, Vasan RS, Beiser AS, et al. Association of carotid artery atherosclerosis with circulating biomarkers of extracel lular matrix remodeling: The Framingham Offspring Study. J Stroke Cerebrovasc Dis,2008,17:412- 417.

共引文献27

同被引文献20

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部